In addition, an in vitro study using pancreatic cancer cells showed that downregulation of USP22 reduced cell stemness and enhanced drug sensitivity by inactivating the Wnt/β‐catenin pathway (Li et al. 2022). The gene discussed is USP22; the disease is familial pancreatic carcinoma.